Genmab A/S Files April 2024 6-K Report
Ticker: GNMSF · Form: 6-K · Filed: Apr 30, 2024 · CIK: 1434265
| Field | Detail |
|---|---|
| Company | Genmab A/S (GNMSF) |
| Form Type | 6-K |
| Filed Date | Apr 30, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, 6-K, reporting
TL;DR
Genmab filed its April 6-K, check S-8 filings for updates.
AI Summary
Genmab A/S filed a Form 6-K on April 30, 2024, to report for the month of April 2024. This filing is incorporated by reference into several of Genmab's S-8 registration statements, including File No. 333-277273.
Why It Matters
This filing serves as an update for investors and indicates ongoing reporting compliance for Genmab A/S, potentially affecting its stock.
Risk Assessment
Risk Level: low — This is a routine reporting filing with no new financial or operational information disclosed.
Key Players & Entities
- Genmab A/S (company) — Registrant
- 333-232693 (dollar_amount) — S-8 Registration Statement File Number
- 333-253519 (dollar_amount) — S-8 Registration Statement File Number
- 333-262970 (dollar_amount) — S-8 Registration Statement File Number
- 333-277273 (dollar_amount) — S-8 Registration Statement File Number
FAQ
What type of filing is this Form 6-K for Genmab A/S?
This Form 6-K is a Report of Foreign Private Issuer pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934.
For which month is this report filed?
This report is filed for the month of April 2024.
What is the filing date of this report?
The filing date is April 30, 2024.
Which registration statements does this 6-K filing get incorporated into?
This 6-K filing is incorporated by reference into Genmab A/S's registration statements on Form S-8, specifically File Nos. 333-232693, 333-253519, 333-262970, and 333-277273.
What is the principal executive office address of Genmab A/S?
The address of the principal executive offices is Carl Jacobsens Vej 30, 2500 Valby, Denmark.
Filing Stats: 229 words · 1 min read · ~1 pages · Grade level 13 · Accepted 2024-04-29 19:10:55
Filing Documents
- tmb-20240430x6k.htm (6-K) — 18KB
- tmb-20240430xex99d1.htm (EX-99.1) — 64KB
- tmb-20240430xex99d1001.jpg (GRAPHIC) — 5KB
- 0001558370-24-006177.txt ( ) — 89KB
From the Filing
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF APRIL 2024 COMMISSION FILE NUMBER 001-38976 Genmab A/S (Exact name of Registrant as specified in its charter) Carl Jacobsens Vej 30 2500 Valby Denmark +45 70 20 27 28 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F Form 40-F This report on Form 6-K shall be deemed to be incorporated by reference in Genmab A/S's registration statements on Form S-8 (File No. 333-232693, 333-253519, 333-262970 and 333-277273 ) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. nthony GENMAB A/S BY: /s/ Anthony Pagano Name: Anthony Pagano Title: Executive Vice President & Chief Financial Officer DATE: APRIL 30, 2024 EXHIBIT INDEX O Exhibit Description of Exhibit 99.1 Company Announcement Dated April 30, 2024: TIVDAK (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical Cancer